Search results for "pooled analysi"

showing 10 items of 48 documents

Air pollution and childhood leukaemia: a nationwide case-control study in Italy

2013

Objectives Leukaemia is the most common cancer in children, but its aetiology is still poorly understood. We tested the hypothesis that traffic-related air pollution is associated with paediatric leukaemia because of chronic exposure to several potential carcinogens. Methods The Italian SETIL study (Study on the aetiology of lymphohematopoietic malignancies in children) was conducted in 14 Italian regions. All incident cases of leukaemia in children aged ≤10 years from these regions (period 1998–2001) were eligible for enrolment. Two controls per case, matched on birth date, gender and region of residence were randomly selected from the local population registries. Exposure assessment at bi…

MalePediatricsAir pollutionNO2Land use Regression ModelLogistic regressionmedicine.disease_causeEconomicaResidence CharacteristicsUSE REGRESSION-MODELSMedicineChildChildrenVehicle EmissionsGeneral Environmental ScienceUSE REGRESSION-MODELS RESIDENTIAL TRAFFIC DENSITY MAGNETIC-FIELDS POOLED ANALYSIS RISK-FACTOR CANCER EXPOSURE CHILDREN NO2 ASSOCIATIONLeukemiaIncidenceIncidence (epidemiology)ASSOCIATIONCANCERChildhood leukaemiaItalyChild PreschoolFemaleCase-Control StudieHumanmedicine.medical_specialtySocio-culturaleMAGNETIC-FIELDSPOOLED ANALYSISRISK-FACTORAir PollutionOccupational ExposureEnvironmental healthTraffic IndicatorHumansEXPOSURERESIDENTIAL TRAFFIC DENSITYExposure assessmentVehicle Emissionbusiness.industryPublic Health Environmental and Occupational HealthCase-control studyAmbientaleInfantCarcinogens EnvironmentalAutomobileCase-Control StudiesResidence CharacteristicDispersion ModelEtiologyGeneral Earth and Planetary SciencesParticulate MatterResidencebusinessAutomobilesOccupational and Environmental Medicine
researchProduct

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in…

2014

BACKGROUND: To further assess the safety profile of the fixed-dose combination of indacaterol and glycopyrronium (QVA149) and its monocomponents; we investigated the impact of individual patient-level factors and time by integrating the patient-level safety data from the QVA149 clinical programme with relevant information from the independent indacaterol and glycopyrronium safety databases.METHODS: Data from 11,404 patients with chronic obstructive pulmonary disease (COPD) were pooled from 14 clinical studies of QVA149, indacaterol and glycopyrronium of ≥3 month's duration with at least two of the treatment groups: QVA149 110/50 μg, glycopyrronium 50 μg, indacaterol 150 μg, placebo or tiotr…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyFixed-dose combinationScopolamine DerivativesQuinolonesPlaceboPooled analysisPulmonary Disease Chronic ObstructiveRisk FactorsInternal medicinemedicineHumansTiotropium BromideIndacaterolAgedCOPDbusiness.industryTiotropiumHazard ratioQVA149Middle Agedmedicine.diseaseGlycopyrrolateConfidence intervalBronchodilator AgentsDrug CombinationsTreatment OutcomeAnesthesiaIndansIndacaterolDrug Therapy CombinationFemaleGlycopyrroniumSafetybusinessBody mass indexMacemedicine.drugRespiratory Medicine
researchProduct

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

2019

Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities(.)(1,2) This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity(3-6). Here we use 2,009 population-based studies, with measurements of height and weight in more than 112 million adults, to report national, regional and global trends in mean BMI segregated by place of residence (a rural or urban area) from 1985 to 2017. We show that, contrary to the dominant paradigm, more than 55% of the global rise in mean BMI from 1985 to 2017-and more than 80% in some low- and middle-income regions…

MaleRural PopulationobesityObesity body mass indexSettore MED/09 - Medicina InternaLetterUrban PopulationEpidemiology[SDV]Life Sciences [q-bio]humanosbody-mass indexadolescenteGeographic MappingSex Factorpaíses desarrolladosRural Health//purl.org/pe-repo/ocde/ford#3.03.09 [https]systematic analysisBody Mass Indexpaíses en desarrollo80 and overrisk factorsAge Factorphysical-activitymediana edadmapeo geográficoAged 80 and overanciano//purl.org/pe-repo/ocde/ford#3.02.18 [https]dietaAge FactorshealthadultoMiddle AgedMultidisciplinary Sciencesadulto joven[SDV] Life Sciences [q-bio]estado nutricionalnutritionScience & Technology - Other TopicsNUTRITIONFemaleHEALTHpooled analysisDiet Healthyworldwide trendsHumanDeveloped CountrieAdultAdolescent//purl.org/pe-repo/ocde/ford#3.03.04 [https]FOOD SYSTEMSocio-culturaleNutritional StatusURBANAdolescent; Adult; Age Factors; Aged; Aged 80 and over; Developed Countries; Developing Countries; Diet Healthy; Female; Geographic Mapping; Humans; Male; Middle Aged; Obesity; Rural Health; Rural Population; Sex Factors; Urban Health; Urban Population; Young Adult; Body Mass Index; Nutritional StatusPOOLED ANALYSISDeveloping CountrieYoung AdultSex FactorsMIDDLE-INCOME COUNTRIESSYSTEMATIC ANALYSISHumansUrban rural Obesity Body-Mass-IndexObesityobesidadDeveloping CountriesAgedMiddle-income countries; obesity; physical-activity; systematic analysis; worldwide trends; pooled analysis; food system; urban; health; nutrition; weightHealthyScience & TechnologyMiddle-income countriesDeveloped Countriesíndice de masa corporalUrban HealthweightDietPHYSICAL-ACTIVITYWORLDWIDE TRENDSRisk factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieWEIGHTfood systemurban
researchProduct

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

2016

AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer. METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin (85 mg/m(2) in over 120 min) followed by leucovorin (400 mg/m(2) in over 120 min), with the addition, after 30 min of irinotecan (180 mg/m(2) in over 90 min) then 5 fluorouracil (5FU) (400 mg/m(2) administred intravenous bolus), followed by 5FU (2400 mg/m2 intraveinous infusion over 46 h)…

MaleTime FactorsOrganoplatinum CompoundsColorectal cancerFOLFIRINOXLeucovorinPooled AnalysisInternational-SocietyKaplan-Meier EstimateOlder PatientsGastroenterology0302 clinical medicineRisk FactorsAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineAged 80 and overAge FactorsGastroenterologyCommon Terminology Criteria for Adverse EventsGeneral Medicine3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisDisease ProgressionFolfirinoxFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFluorouracilFranceFolfirinox RegimenColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyOxaliplatin FolfirinoxIrinotecanDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesPancreatic CancerRetrospective StudyInternal medicinePancreatic cancermedicineHumansChemotherapyGeriatric AssessmentAgedRetrospective StudiesColorectal CancerChi-Square DistributionPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyElderly Patientsmedicine.diseasePhase-Ii Trial1st-Line TreatmentSurgeryPancreatic NeoplasmsIrinotecanRegimenMultivariate AnalysisCamptothecinOpen-LabelFeasibility TreatmentTomography X-Ray Computedbusiness
researchProduct

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis…

2020

BACKGROUND: Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents.

Malebody-mass indexADULTHOODAdolescentspituuskasvuPediatricsBody Mass Index0302 clinical medicineChild DevelopmentnuoretPublic health surveillanceMedicineHealth Status Indicators10. No inequalityChild11 Medical and Health SciencesBody mass indexComputingMilieux_MISCELLANEOUSeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801General MedicineBody mass indexeskansainvälinen vertailu3. Good healthGeographyHealth030220 oncology & carcinogenesisChild PreschoolMedical and Health sciences//purl.org/becyt/ford/3 [https]medicine.medical_specialtySchool-aged adolescentsSocio-culturalelapset (ikäryhmät)Nursing.territoriesravinto//purl.org/becyt/ford/3.3 [https]03 medical and health sciencesSchool ChildrenSDG 3 - Good Health and Well-beingSYSTEMATIC ANALYSISHumansschool-aged children and adolescentsMontenegroeducationScience & TechnologyOmvårdnadHealth sciences Medical and Health sciencesCiências médicas e da saúdeBayes TheoremAnthropometryAdolescent Developmentmedicine.diseaseTRENDSHeight and Body-mass IndexFaculdade de Ciências SociaisUNDERNUTRITIONHeight index trajectoriesHeight body mass index children epidemiologybody-mass index; school-aged children and adolescents; risk factors growthStatureBody mass indexDemographySettore MED/09 - Medicina InternaInternationality[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyBody-mass index trajectoriesEpidemiologyMedicine and Health Sciencesrisk factorscountriesEPIDEMIOLOGYheight ; body-mass index ; children ; adolescents ; BMI030212 general & internal medicinepainoindeksiChild development2. Zero hungerMedicine(all)School age childobestity children cardiovascularPopulation Health1. No povertyPediatrikPublic Health Global Health Social Medicine and Epidemiology3142 Public health care science environmental and occupational healthPeer reviewPooled analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNUTRITIONFemalemedicine.symptompooled analysis/dk/atira/pure/subjectarea/asjc/2700Life Sciences & Biomedicineterveysheight BMI nutrition health children adolescentsAdolescentgrowthPopulationbody-massPopulation basedBody-mass indexBMIYoung AdultMedicine General & InternalchildrenMeta-Analysis as TopicGeneral & Internal Medicineparasitic diseasesWeight gainSchool-aged childrensAge trajectoriesbusiness.industryHeightWeightBody HeightFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMalnutritionONSETCiências da Saúde Ciências médicas e da saúdeSchool-aged childrenVDP::Medical disciplines: 700::Health sciences: 800::Community medicine Social medicine: 801businessWeight gainterveysriskitEstilos de Vida e Impacto na Saúde
researchProduct

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in pati…

2015

Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free su…

OncologyAdultAdjuvant taxanesCancer Researchmedicine.medical_specialtyAnthracyclinemedicine.medical_treatmenteducationBreast NeoplasmsDocetaxelDisease-Free SurvivalPooled analysisBreast cancerBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIn patientAnthracyclinesOestrogen receptorProspective StudiesAgedER positivebusiness.industryMiddle Agedmedicine.diseaseImmunohistochemistryPooled analysisKi-67 AntigenOncologyDocetaxelBreast international groupChemotherapy AdjuvantFemaleTaxoidsbusinessAdjuvantKi67medicine.drug
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium

2016

Background: Various occupations have been associated with an elevated risk of non-Hodgkin lymphoma (NHL), but results have been inconsistent across studies. Objectives: We investigated occupational risk of NHL and of four common NHL subtypes with particular focus on occupations of a priori interest. Methods: We conducted a pooled analysis of 10,046 cases and 12,025 controls from 10 NHL studies participating in the InterLymph Consortium. We harmonized the occupational coding using the 1968 International Standard Classification of Occupations (ISCO-1968) and grouped occupations previously associated with NHL into 25 a priori groups. Odds ratios (ORs) adjusted for center, age, and sex were det…

OncologyAdultMalemedicine.medical_specialtyAdolescentHealth Toxicology and MutagenesisMEDLINEReviewBarbering03 medical and health sciences0302 clinical medicineimmune system diseasesRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHumans030212 general & internal medicineAgedAged 80 and overbusiness.industryExtramuralPublic healthLymphoma Non-HodgkinPublic Health Environmental and Occupational HealthCase-control studyAgricultureMiddle Agedmedicine.disease030210 environmental & occupational healthSeguretat en el treballLymphomaMalaltia de HodgkinOccupational DiseasesPooled analysisMeta-analysisCase-Control StudiesTextile IndustryHodgkin lymphomaIndustrial safetyFemaleHodgkin's diseasebusinessOccupation - non-hodgkin lymphomaEnvironmental Health Perspectives
researchProduct

Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advan…

2014

3575 Background: After the use of preoperative radiotherapy and TME, survival of LARC has reached a plateau. More effective therapies, predictive/prognostic factors for treatment selection and vali...

OncologyCancer Researchmedicine.medical_specialtyChemotherapyPreoperative radiotherapybusiness.industryColorectal cancermedicine.medical_treatmentLocally advancedmedicine.diseaseSurgeryPooled analysisOncologyInternal medicinemedicinesense organsbusinessChemoradiotherapyJournal of Clinical Oncology
researchProduct

Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis o…

2013

e20028 Background: Adjuvant high-dose interferon (HDI) treatment of patients (pts) with malignant melanoma (MM) consists of 4 weeks intravenous (IV) induction with 20 MU/m² interferon (IFN) alpha 2b followed by 11 months of 10 Mio IU/m² IFN subcutaneously (sc). It is unclear whether both parts of the regimen are mandatory for the efficacy of HDI treatment. The adjuvant phase III trials DeCOG MM-ADJ-5 and the Italian Melanoma Intergroup (IMI) trial evaluated intermittent IV HDI (iHDI) regimens as compared to standard HDI. In both trials, the experimental arm consisted of iHDI for 3 or 4 cycles, respectively. To gain more insight into the role of iHDI in the adjuvant setting we performed a p…

OncologyCancer Researchmedicine.medical_specialtyPhase iii trialsbusiness.industryMelanomamedicine.medical_treatmentAlpha interferonmedicine.diseasePooled analysisOncologyInterferonInternal medicineImmunologymedicineStage (cooking)businessAdjuvantmedicine.drugJournal of Clinical Oncology
researchProduct